Healthcare
Alcohol use disorder is common among the population for a very long time. Adial is planning to leverage genomics that can treat pervasive alcohol use disorder.
New data from Roche’s study on the use of Ocrevus to treat patients with primary and secondary progressive multiple sclerosis demonstrated positive outcomes.
The FDA requested additional data analyses from the pediatric studies that Merck stated it has submitted. The final decision is expected on July 1, 2022.
Despite being represented in clinical research, no solutions have been found to circumvent the effects of Alopecia areata. However, there may be hope.
Although it looks that we’re on the downside of the COVID-19 pandemic in the U.S., biopharma companies are still working on developing better treatments and preventions.
In his State of the Union Address earlier this year, President Joe Biden called for a $35 cap on insulin costs that are provided by insurance programs.
Civica plans to make versions of three affordable insulins available at significantly reduced costs by 2024. You can explore the other aspirations here in this article.
Roche has partnered with BMS to utilize two digital pathology platforms that would advance research into solid tumor treatment options for patients.
In honor of March 24, World TB Day, BioSpace looks at clinical trials and eradication efforts occurring today.
A recent study in mice was able to halt memory decay in a model of Alzheimer’s disease. Another study found that even mild infection increased the risk of new-onset type 2 diabetes, although the risk increased with the severity of COVID-19.
PRESS RELEASES